Here's What Key Metrics Tell Us About Amgen (AMGN) Q4 Earnings

Core Insights - Amgen reported revenue of $9.87 billion for the quarter ended December 2025, reflecting an 8.6% increase year-over-year and a surprise of +4.23% over the Zacks Consensus Estimate of $9.47 billion [1] - The earnings per share (EPS) was $5.29, slightly down from $5.31 in the same quarter last year, with an EPS surprise of +11.18% compared to the consensus estimate of $4.76 [1] Financial Performance Metrics - Amgen's stock has returned +7.5% over the past month, outperforming the Zacks S&P 500 composite's +1.8% change, and currently holds a Zacks Rank 3 (Hold) [3] - Product sales for BLINCYTO in the U.S. were $270 million, which is a +10.2% change year-over-year but below the estimated $283.5 million [4] - KYPROLIS sales in the ROW were $111 million, representing an -18.4% change year-over-year, also below the estimated $130.37 million [4] - Repatha sales in the U.S. reached $517 million, exceeding the estimate of $451.25 million, marking a +64.1% year-over-year increase [4] - Other revenues amounted to $499 million, surpassing the average estimate of $396.39 million, reflecting a +34.9% year-over-year change [4] - Total product sales were $9.37 billion, exceeding the average estimate of $9.09 billion, with a year-over-year change of +7.5% [4] - Otezla sales totaled $625 million, slightly above the estimate of $621.09 million, with a year-over-year change of +0.2% [4] - Total sales for KYPROLIS were $351 million, below the estimate of $362.31 million, representing a -5.7% year-over-year change [4] - Total sales for BLINCYTO were $413 million, below the estimate of $435.33 million, with an +8.4% year-over-year change [4] - Total sales for Repatha reached $870 million, exceeding the estimate of $811.51 million, marking a +43.6% year-over-year increase [4] - Total sales for XGEVA were $447 million, slightly below the estimate of $453.76 million, representing a -20.3% year-over-year change [4] - Total sales for Prolia were $1.05 billion, exceeding the estimate of $974.58 million, with a -9.5% year-over-year change [4]